Picture loading failed.

Anti-EGFR;LGR5 therapeutic antibody (Pre-made Petosemtamab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Petosemtamab (also known as MCLA 158) is a bispecific, full length human IgG antibody being developed by Merus, for the treatment of solid tumours including.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-440-1mg 1mg 3090
GMP-Bios-ab-440-10mg 10mg 21890
GMP-Bios-ab-440-100mg 100mg 148000
GMP-Bios-ab-440-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-EGFR;LGR5 therapeutic antibody (Pre-made Petosemtamab biosimilar,Bispecific mAb)
INN Name Petosemtamab
TargetEGFR;LGR5
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2019
Year Recommended2020
CompaniesMerus
Conditions Approvedna
Conditions ActiveColorectal cancer;Solid tumours
Conditions Discontinuedna
Development Techna